Deep
PSMA
Comprehensive Tumor Analysis
DeepPSMA automatically detects, stages, and quantifies prostate cancer on PSMA-PET/CT scans.
With 92% detection accuracy and seamless radiology integration, it empowers imaging teams to deliver standardized, actionable reports — faster.
How
DeepPSMA Works
DeepPSMA streamlines PSMA-PET/CT interpretation — from image upload to structured reporting — delivering fast, consistent insights for clinical decision-making.
PSMA-PET/CT Image Upload
1
Upload PSMA-PET/CT imaging data securely to Nucs Al's platform, ensuring privacy and confidentiality.
DeepPSMA Al-analysis
2
Once a PSMA-PET/CT scan is uploaded, DeepPSMA automatically detects lesions, stages disease, and quantifies whole-body tumor burden.
Physician Assessment
3
Physicians review and validate findings directly within the interface, with the ability to make edits before generating a structured, shareable report.
Report Generation
4
The result: faster turnaround, consistent reporting, and scalable precision for prostate cancer imaging.
Key Features
DeepPSMA delivers intelligent automation across critical steps of PSMA-PET CT interpretation — streamlining detection, staging, and quantification to accelerate clinical workflows and enhance diagnostic accuracy.
Accurate Detection
Automatically identifies PSMA-avid tumor lesions across the body, enhancing diagnostic confidence and reducing oversight.
Cancer Staging
Localizes lesions by TNM classification with high precision - enabling consistent, structured staging as part of every report.
Tumor Quantification
Calculates whole-body tumor burden metrics, including volume and SUV values, supporting treatment planning and monitoring.
Audience Value Overview
DeepPSMA delivers measurable value to every stakeholder.
DeepPSMA improves accuracy, efficiency, and decision-making across the prostate cancer care ecosystem. Whether you're reading scans, designing trials, or investing in next-gen technology, DeepPSMA brings tangible impact.
Clinical Applications
SelectPSMA supports clinical decision-making by identifying patients most likely to benefit from PSMA-targeted therapies. From therapy planning to trial enrollment, SelectPSMA adds precision at every stage, helping clinicians personalize care with confidence.
Clinical Diagnostics
Standardizes detection and staging of PSMA-positive prostate cancer.
Trial Imaging
Provides quantitative tumor burden and TNM scores across large datasets.
Report Generation
Generate a report summarizing key quantification results and metrics, including extracted miTNM classification to support clinical reporting.
Radiomics / Research
Export structured data in a CSV to support biomarker discovery, response modeling, and radiomics.
negative predictive value for identifying non-responders
higher risk of progression for non-responders vs responders
higher risk of death for non-responders vs responders
Accuracy in PSMA-positive lesion detection
Accuracy in TNM staging
Accuracy in whole-body tumor quantification
Frequently asked questions
DeepPSMA streamlines interpretation by automatically identifying PSMA-avid lesions, staging them according to TNM classification, and calculating tumor burden metrics (including volume and SUV values).
DeepPSMA supports any PSMA tracer, it is PSMA agnostic.
Based on internal studies, DeepPSMA demonstrates 92% accuracy in detecting PSMA-positive lesions, 87% accuracy in TNM staging, and 99% accuracy in lesion quantification.
DeepPSMA is not yet CE marked or FDA cleared, but both are in progress.
To request access to DeepPSMA for investigational use, please get in touch with us through the 'Contact Us' button above.
The Nucs AI platform features an intuitive interface, complemented by comprehensive training, dedicated support, and reliable troubleshooting to ensure seamless integration into your workflow.